June 25, 2019

The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results.  However, it is not out of the question that a Phase III study can meet its efficacy endpoint, yet still be rejected by the FDA.  This may especially...

Please reload

THE GENE

EXPRESS

Recent News

Sick factor

June 2, 2020

Fast and spurious

June 2, 2020

Screen stars

June 2, 2020

1/4
Please reload

Tags

Please reload

 

Follow us:

©2018-2020 GeneCentrix, Inc.